Abstract
Zika virus (ZIKV) is a mosquito-borne virus that has a high risk of inducing Guillain–Barré syndrome and microcephaly in newborns. Because vaccination is considered the most effective strategy against ZIKV infection, we designed a recombinant vaccine utilizing the baculovirus expression system with two strains of ZIKV envelope protein (MR766, Env_M; ZBRX6, Env_Z). Animals inoculated with Env_M and Env_Z produced ZIKV-specific antibodies and secreted effector cytokines such as interferon-γ, tumor necrosis factor-α, and interleukin-12. Moreover, the progeny of immunized females had detectable maternal antibodies that protected them against two ZIKV strains (MR766 and PRVABC59) and a Dengue virus strain. We propose that the baculovirus expression system ZIKV envelope protein recombinant provides a safe and effective vaccine strategy.
Highlights
Zika virus (ZIKV) is a mosquito-borne virus that has a high risk of inducing Guillain–Barré syndrome and microcephaly in newborns
We propose that the baculovirus expression system ZIKV envelope protein recombinant provides a safe and effective vaccine strategy
We designed a ZIKV recombinant subunit vaccine incorporating the baculovirus expression system that is potentially applicable to humans because of its higher level (~ 1.5 times) of recombinant protein production than bacterial systems and its ability to incorporate mammal-like posttranslational modifications[16]
Summary
Zika virus (ZIKV) is a mosquito-borne virus that has a high risk of inducing Guillain–Barré syndrome and microcephaly in newborns. Because vaccination is considered the most effective strategy against ZIKV infection, we designed a recombinant vaccine utilizing the baculovirus expression system with two strains of ZIKV envelope protein (MR766, Env_M; ZBRX6, Env_Z). The progeny of immunized females had detectable maternal antibodies that protected them against two ZIKV strains (MR766 and PRVABC59) and a Dengue virus strain. We propose that the baculovirus expression system ZIKV envelope protein recombinant provides a safe and effective vaccine strategy. We developed a ZIKV recombinant subunit vaccine (Env_M, Env_Z) utilizing the E proteins from an epidemic Brazilian strain (ZBRX6) and the original strain (MR766). Animals immunized with the recombinant subunit vaccine demonstrated induced humoral and cellular immunity against these two ZIKV strains. We designed a ZIKV recombinant subunit vaccine incorporating the baculovirus expression system that is potentially applicable to humans because of its higher level (~ 1.5 times) of recombinant protein production than bacterial systems and its ability to incorporate mammal-like posttranslational modifications[16]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.